117 related articles for article (PubMed ID: 20620976)
1. Signalling to drug resistance in CLL.
Hertlein E; Byrd JC
Best Pract Res Clin Haematol; 2010 Mar; 23(1):121-31. PubMed ID: 20620976
[TBL] [Abstract][Full Text] [Related]
2. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
4. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
López-Guerra M; Roué G; Pérez-Galán P; Alonso R; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2009 Apr; 15(8):2767-76. PubMed ID: 19351760
[TBL] [Abstract][Full Text] [Related]
5. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
6. Preclinical assessment of curcumin as a potential therapy for B-CLL.
Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
[TBL] [Abstract][Full Text] [Related]
7. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Ciucci A; Gianferretti P; Piva R; Guyot T; Snape TJ; Roberts SM; Santoro MG
Mol Pharmacol; 2006 Nov; 70(5):1812-21. PubMed ID: 16908599
[TBL] [Abstract][Full Text] [Related]
9. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.
Muzio M; Scielzo C; Bertilaccio MT; Frenquelli M; Ghia P; Caligaris-Cappio F
Br J Haematol; 2009 Feb; 144(4):507-16. PubMed ID: 19036098
[TBL] [Abstract][Full Text] [Related]
11. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
13. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
14. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells.
Ling MT; Wang X; Ouyang XS; Xu K; Tsao SW; Wong YC
Oncogene; 2003 Jul; 22(29):4498-508. PubMed ID: 12881706
[TBL] [Abstract][Full Text] [Related]
15. Targeting NF-kappaB in hematologic malignancies.
Braun T; Carvalho G; Fabre C; Grosjean J; Fenaux P; Kroemer G
Cell Death Differ; 2006 May; 13(5):748-58. PubMed ID: 16498458
[TBL] [Abstract][Full Text] [Related]
16. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Lin K; Glenn MA; Harris RJ; Duckworth AD; Dennett S; Cawley JC; Zuzel M; Slupsky JR
Cancer Res; 2006 Aug; 66(15):7801-9. PubMed ID: 16885384
[TBL] [Abstract][Full Text] [Related]
17. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
18. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.
Buggins AG; Pepper CJ
Leuk Res; 2010 Jul; 34(7):837-42. PubMed ID: 20359747
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of NF-kappaB signaling: 785 and counting.
Gilmore TD; Herscovitch M
Oncogene; 2006 Oct; 25(51):6887-99. PubMed ID: 17072334
[TBL] [Abstract][Full Text] [Related]
20. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]